Clinical Trial Design and Selected Drug Safety Issues for Antibiotics Used to Treat Community‐Acquired Pneumonia
Open Access
- 1 December 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (S3), S176-S179
- https://doi.org/10.1086/591400
Abstract
High-quality evaluations of both efficacy and safety are essential to characterize the risk-benefit profile of antibiotics. The current US Food and Drug Administration guidelines on trial design for community-acquired pneumonia have several weaknesses, including the failure to insist on the use of double blinding and intention-to-treat analysis. A primary difficulty with noninferiority designs is that poorly conducted studies, which increase noise, are biased toward the conclusion of noninferiority even in the presence of important differences between the test drug and the control drug. Additionally, results of noninferiority trials, in the absence of a well-established anchor, may be difficult to interpret. The US Food and Drug Administration drug-evaluation process includes preclinical studies to assess toxicity and a series of clinical studies involving humans to define efficacy and to identify potential safety problems. When signals are apparent, as they were for telithromycin (liver toxicity in rats, dogs, and monkeys) or for sparfloxacin (prolongation of the QT interval in dogs), it is nonetheless essential that these signals are fully and fairly evaluated in human studies with adequate power. Risks of antibiotic use, such as prolongation of the corrected QT interval and sudden death, may be acceptable in the presence of convincing benefits for patients with severe, life-threatening infections; however, the risk-benefit profile derived from severe infections cannot necessarily be generalized to mild or self-limited infections, for which the same serious drug-associated risks are likely to exceed the benefits. Complete and proper evaluation of both safety and efficacy in specific situations is essential to define the risk-benefit profiles of all drugs, including antibiotics.Keywords
This publication has 23 references indexed in Scilit:
- The FDA and the Case of KetekNew England Journal of Medicine, 2007
- Ketek — The FDA PerspectiveNew England Journal of Medicine, 2007
- Telithromycin and Acute Liver FailureNew England Journal of Medicine, 2006
- Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin TherapyClinical Infectious Diseases, 2006
- A Randomized Trial Comparing the Cardiac Rhythm Safety of Moxifloxacin vs Levofloxacin in Elderly Patients Hospitalized With Community-Acquired PneumoniaChest, 2005
- Antimicrobial Safety: Focus on FluoroquinolonesClinical Infectious Diseases, 2005
- Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysisBMJ, 2005
- Therapeutic-Class Wars -- Drug Promotion in a Competitive MarketplaceNew England Journal of Medicine, 1994
- Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal PneumoniaAnnals of Internal Medicine, 1964
- Treatment of Pneumococcal Pneumonia with PenicillinNew England Journal of Medicine, 1945